Search | IOVS | ARVO Journals

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

View

Showing 1 – 20 of 24

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract May 2006

Safety and Drug Release Profile of Injectable Intravitreal Sustained–Release Fluocinolone Acetonide Device

R.F. See; J.J. Peairs; S. Srivastava; P. Mruthyunjaya; S.S. Stinnett; H. Guo; M. Nazzaro; P. Ashton; G.J. Jaffe

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):5119.

ARVO Annual Meeting Abstract May 2006

Fluocinolone Acetonide Sustained Drug Delivery Device for Chronic Retinal Venous Occlusive Disease

R.S. Ramchandran; S.S. Stinett; G.J. Jaffe

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):5907.

ARVO Annual Meeting Abstract May 2006

Pre–Treatment Prognosticators of Response to a Fluocinolone Acetonide Implant for Diabetic Macular Edema

S. Ahmad; S.S. Stinnett; G.J. Jaffe

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):979.

ARVO Annual Meeting Abstract May 2006

Fluocinolone Acetonide Intravitreal Implant to Treat Posterior Segment Uveitis: 3–Year Results of a Multi–Center Clinical Trial

G.J. Jaffe; D.F. Martin; D. Callanan; B. Levy; T. Comstock; Fluocinolone Acetonide Implant Uveitis Study Group

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):1523.

ARVO Annual Meeting Abstract May 2006

A Progress Report on the TheraSight Ocular Brachytherapy Safety and Feasibility Study

G. Hubbard, III; T. Ciulla; J. Heier, Jr.; M. Zarbin; G.J. Jaffe

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):2101.

ARVO Annual Meeting Abstract May 2006

OCT Reading Center Grader Agreement for OCT in Neovascular Age–Related Macular Degeneration

N. Zhang; G.C. Hoffmeyer; E.S. Young; R.E. Burns; K.P. Winter; S.S. Stinnett; C.A. Toth; G.J. Jaffe

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):2178.

ARVO Annual Meeting Abstract May 2006

The in vitro Efficacy of Combining Temozolomide With O6–Benzylguanine in Human Choroidal Melanoma Cell Lines

R. Tano; J.S. Yoo; D.S. Tyler; C. Augustine; F. Ali–Osman; H.S. Friedman; S.S. Stinnett; G.J. Jaffe; P. Mruthyunjaya

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):2248.

ARVO Annual Meeting Abstract May 2006

The Utility Of Diagnostic Testing In Uveitis Patients

S. Srivastava; P. Mruthyunjaya; P. Mettu; S. Bressler; R. McCallum; G.J. Jaffe

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):2442.

ARVO Annual Meeting Abstract May 2006

The Importance of Bcl–xL to the Survival of Human RPE Cells

J.J. Peairs; N. Zhang; P. Yang; J. Roberts; R. Kole; G.J. Jaffe

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):2858.

ARVO Annual Meeting Abstract May 2006

Role of Caspase–8 in RPE Cell Resistance to TNF––Mediated Cell Death

P. Yang; J.J. Peairs; J.L. Wiser; G.J. Jaffe

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):2859.

ARVO Annual Meeting Abstract May 2005

OCT Reading Center Inter– and Intra–Grader Agreement for Diabetic Macular Edema

C. Castellano; G. Hoffmeyer; E. Young; K. Winter; S.S. Stinnett; C.A. Toth; G.J. Jaffe

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):262.

ARVO Annual Meeting Abstract May 2005

Association Between Pre–Treatment Variables and Response to Intravitreal Triamcinolone Acetonide Injection in Diabetic Macular Edema

S. Ahmad; S.S. Stinnett; G.J. Jaffe

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):1464.

ARVO Annual Meeting Abstract May 2005

Fluocinolone Acetonide Intravitreal Implant to Treat Posterior Uveitis: 2–year Results of a Multi–Center Clinical Trial

G.J. Jaffe; D. Martin; D. Callanan; B. Levy; Fluocinolone Acetonide Implant Uveitis Study Group

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):2386.

ARVO Annual Meeting Abstract May 2005

A New Ocular Brachytherapy System for the Treatment of Exudative AMD

G. Hubbard; T. Ciulla; D.M. Marcus; J. Heier; M. Zarbin; G.J. Jaffe; N. Bhagat; E. Buckley; T.M. Aaberg, Sr

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):2425.

ARVO Annual Meeting Abstract May 2005

Uveitis in the Elderly: Epidemiological Data From the National Long Term Care Survey Medicare Cohort

S.W. Reeves; F.A. Sloan; P.P. Lee; L. Van Scoyoc; G.J. Jaffe

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):5011.

ARVO Annual Meeting Abstract May 2005

Human RPE Cell Survival Factor Gene Expression in situ Compared to Expression in vitro

J.J. Peairs; P. Yang; Z.J. Zavodni; J.N. Ebright; C. Bowes Rickman; G.J. Jaffe

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):5368.

ARVO Annual Meeting Abstract May 2005

Hydrogen Peroxide– and Growth Factor–Mediated Akt Activation in Human RPE Cells

P. Yang; J.J. Peairs; G.J. Jaffe

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):1595.

ARVO Annual Meeting Abstract May 2004

SRF Exposure Up–Regulates Cytokine and Anti–Apoptotic Factor Expression in Cultured Human RPE Cells

J.L. Wiser; J.N. Ebright; C. Bowes Rickman; G.J. Jaffe

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):4607.

ARVO Annual Meeting Abstract May 2004

Evaluation of Image Artifact Produced by Optical Coherence Tomography of Retinal Pathology

R. Ray; S.S. Stinnett; G.J. Jaffe

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):3006.

ARVO Annual Meeting Abstract May 2004

Effect of TNF– on survival factor expression in human RPE cells

P. Yang; J.L. Wiser; J.B. Allen; G.J. Jaffe

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):3191.

1 2

Next 20 Results »

Advertisement